These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39013086)

  • 1. [Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1].
    Svajda L; Cserepes M; Hegyi B; Niczky T; Tóvári J
    Magy Onkol; 2024 Jul; 68(2):126-135. PubMed ID: 39013086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
    Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
    Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability.
    Qiu J; Zhong F; Zhang Z; Pan B; Ye D; Zhang X; Yao Y; Luo Y; Wang X; Tang N
    Int Immunopharmacol; 2024 Jul; 136():112415. PubMed ID: 38850791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.
    Tawadros AIF; Khalafalla MMM
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1063-S1069. PubMed ID: 30539847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.
    Zou MZ; Liu WL; Li CX; Zheng DW; Zeng JY; Gao F; Ye JJ; Zhang XZ
    Small; 2018 Jul; 14(28):e1801120. PubMed ID: 29882235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
    Noman MZ; Desantis G; Janji B; Hasmim M; Karray S; Dessen P; Bronte V; Chouaib S
    J Exp Med; 2014 May; 211(5):781-90. PubMed ID: 24778419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
    Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
    Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia.
    Qiang L; Hong L; Jian X; Zhanlin Z
    Int Immunopharmacol; 2023 May; 118():110010. PubMed ID: 36924563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
    Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
    Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
    Liu S; Qin T; Liu Z; Wang J; Jia Y; Feng Y; Gao Y; Li K
    Cell Death Dis; 2020 May; 11(5):309. PubMed ID: 32366856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
    Takaki H; Hirata Y; Ueshima E; Kodama H; Matsumoto S; Wada R; Suzuki H; Nakasho K; Yamakado K
    J Vasc Interv Radiol; 2020 Sep; 31(9):1475-1482.e2. PubMed ID: 32800663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunorthodontics: PD-L1, a Novel Immunomodulator in Cementoblasts, Is Regulated by HIF-1α under Hypoxia.
    Yong J; Gröger S; von Bremen J; Meyle J; Ruf S
    Cells; 2022 Jul; 11(15):. PubMed ID: 35954195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
    Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
    J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia.
    Ding XC; Wang LL; Zhang XD; Xu JL; Li PF; Liang H; Zhang XB; Xie L; Zhou ZH; Yang J; Weichselbaum RR; Yu JM; Hu M
    J Hematol Oncol; 2021 Jun; 14(1):92. PubMed ID: 34118979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
    Cao Y; Li W; Wang Z; Pang H
    Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.